Fibroblast activation protein binding agents and use thereof
AssigneeOrionis Biosciences BV
InventorsNikolai Kley, Erik Depla, Lennart Zabeau
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to agents, chimeric proteins and protein complexes that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents, chimeric proteins and protein complexes and their use in the treatment of various diseases.
Claims17
A fibroblast activation protein (FAP) binding agent comprising a targeting moiety comprising a recombinant heavy chain only antibody (VHH) or a humanized VHH, wherein the targeting moiety comprises three complementarity determining regions (CDR1, CDR2, and CDR3), wherein
- (a) CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1108, 1096, 1103, 1104, or 111;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 128;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 159;
- (b) CDR1 comprises the amino acid sequence of SEQ ID NO:
- 1128, 1129, 1110, 1111, 1117, 1118, 1119, 1121, 1122, 1123, 1126, or 855;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 126;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 157;
- (c) CDR1 comprises the amino sequence of SEQ ID NO:
- 111;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 128;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 156;
- (d) CDR1 comprises the amino sequence of SEQ ID NO:
- 89;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 128;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 159;
- (e) CDR1 comprises the amino sequence of SEQ ID NO:
- 111;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 129;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 156;
- (f) CDR1 comprises the amino sequence of SEQ ID NO:
- 115;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 128;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 159;
- (g) CDR 1 comprises the amino sequence of SEQ ID NO:
- 107;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 128;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 169;
- (h) CDR 1 comprises the amino sequence of SEQ ID NO:
- 115;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 128;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 156;
- (i) CDR1 comprises the amino sequence of SEQ ID NO:
- 855;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 125;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 157;
- or
- (j) CDR1 comprises the amino sequence of SEQ ID NO:
- 97;
- CDR2 comprises the amino acid sequence of SEQ ID NO:
- 119;
- and CDR3 comprises the amino acid sequence of SEQ ID NO:
- 159.
Dependencies are inferred from the claim text.